Yao Yan

Yao Yan

Auto-generated profile, based on publicly available information

Yao Yan

Sage Bionetworks, Seattle, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
CYChao Yan
Chao Yan
YYYao Yan
Yao Yan
ZWZhiyu Wan
Zhiyu Wan
ZZZiqi Zhang
Ziqi Zhang
LOLarsson Omberg
Larsson Omberg
BMBradley A. Malin
Bradley A. Malin
Synthetic health data have the potential to mitigate privacy concerns in supporting biomedical research and healthcare applications. Modern approaches for data generation continue to evolve and demonstrate remarkable potential. Yet there is a lack of a systematic assessment framework to benchmark methods as they emerge and determine which methods are most appropriate for which use cases. In this work, we introduce a systematic benchmarking framework to appraise key characteristics with respect to utility and privacy metrics. We apply the framework to evaluate synthetic data generation methods for electronic health records data from two large academic medical centers with respect to several use cases. The results illustrate that there is a utility-privacy tradeoff for sharing synthetic health data and further indicate that no method is unequivocally the best on all criteria in each use case, which makes it evident why synthetic data generation methods need to be assessed in context.

10 July 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NSNoha Sharafeldin
Noha Sharafeldin
BBBenjamin Bates
Benjamin Bates
QSQianqian Song
Qianqian Song
VMVithal Madhira
Vithal Madhira
YYYao Yan
Yao Yan
UTUmit Topaloglu
Umit Topaloglu
PURPOSE: Variation in risk of adverse clinical outcomes in patients with cancer and COVID-19 has been reported from relatively small cohorts. The NCATS’ National COVID Cohort Collaborative (N3C) is a centralized data resource representing the largest multicenter cohort of COVID-19 cases and controls nationwide. We aimed to construct and characterize the cancer cohort within N3C and identify risk factors for all-cause mortality from COVID-19.METHODS: We used 4,382,085 patients from 50 US medical centers to construct a cohort of patients with cancer. We restricted analyses to adults ≥ 18 years old with a COVID-19–positive or COVID-19–negative diagnosis between January 1, 2020, and March 25, 2021. We followed N3C selection of an index encounter per patient for analyses. All analyses were performed in the N3C Data Enclave Palantir platform.RESULTS: A total of 398,579 adult patients with cancer were identified from the N3C cohort; 63,413 (15.9%) were COVID-19–positive. Most common represented cancers were skin (13.8%), breast (13.7%), prostate (10.6%), hematologic (10.5%), and GI cancers (10%). COVID-19 positivity was significantly associated with increased risk of all-cause mortality (hazard ratio, 1.20; 95% CI, 1.15 to 1.24). Among COVID-19–positive patients, age ≥ 65 years, male gender, Southern or Western US residence, an adjusted Charlson Comorbidity Index score ≥ 4, hematologic malignancy, multitumor sites, and recent cytotoxic therapy were associated with increased risk of all-cause mortality. Patients who received recent immunotherapies or targeted therapies did not have higher risk of overall mortality.CONCLUSION: Using N3C, we assembled the largest nationally representative cohort of patients with cancer and COVID-19 to date. We identified demographic and clinical factors associated with increased all-cause mortality in patients with cancer. Full characterization of the cohort will provide further insights into the effects of COVID-19 on cancer outcomes and the ability to continue specific cancer treatments.

26 October 2011 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
WSwei shi
wei shi
PGpeipei gong
peipei gong
JFJian Fan
Jian Fan
YYYao Hua Yan
Yao Hua Yan
LNLanchun Ni
Lanchun Ni
JCJian Chen
Jian Chen